Insperity | Crafting a New Verbal Brand

March 11, 2011

Verbal Branding: Corporate Identity With directives from Market Research and Brand Strategy, the Verbal Branding team embarked on creative for the new identity. With all of our core competencies in house, it was an easy project transition to move from strategy into naming. The Verbal Branding team worked closely with the Brand Strategy team to […]

Continue Reading

FDA Approval: Edarbi

February 28, 2011

FDA approves Edarbi to treat high blood pressure (source: FDA Press Announcement) On Friday, February 25, 2011, The U.S. Food and Drug Administration approved Edarbi tablets (azilsartan medoxomil) to treat high blood pressure (hypertension) in adults. Data from clinical studies showed Edarbi to be more effective in lowering 24-hour blood pressure compared with two other […]

Continue Reading

Valentine’s Guide for the Guys

February 10, 2011

Valentine’s Day is historically geared towards the ladies … a pink & red inspired holiday with iconic imagery of hearts and chocolates and roses. This year, we thought we’d refocus the Vday brand on the guys instead, and tapped into some of our own to find out what they would like for this ‘holiday.’ Some […]

Continue Reading

EMA Approval: Jonexa

January 31, 2011

Jonexa (hylastan) is a bacterially fermented product derived from hyaluronan that is indicated for the treatment of pain associated with OA of the knee and administered in one or two injections. Genzyme expects to launch Jonexa in select European Union markets and Hong Kong in 2010 because they believe opportunity exists in those markets for […]

Continue Reading

FDA Approval: Viibryd

January 24, 2011

Clinical Data, Inc. (NASDAQ: CLDA), today announced that the U.S. Food and Drug Administration (FDA) has approved vilazodone HCl tablets, to be marketed under the brand name Viibryd™, for the treatment of adults with major depressive disorder (MDD). Viibryd is a new molecular entity and the first and only selective serotonin reuptake inhibitor and 5HT1A […]

Continue Reading

Starbucks Goes Bigger

January 18, 2011

On the heels of the new logo debut last week, Starbucks announced a new drink size for its iced beverages on Sunday. “Trenta” will be a 31oz size specifically for iced coffee, iced tea and iced tea lemonade drinks in the United States (read: Venti is still the largest you coffee addicts can get for […]

Continue Reading

FDA Approval: Brilique

December 06, 2010

LONDON, Dec 6 (Reuters) – AstraZeneca’s new heart medicine Brilique — or Brilinta — won final clearance from EU regulators on Monday, putting it on track to compete with Plavix, the world’s second biggest-selling drug, next year. AstraZeneca is relying on revenues from the new product to offset expiring patents on some of its best-selling […]

Continue Reading

FDA Approval: Halaven

November 16, 2010

FDA Approves Eisai Inc. (ESALF.PK)’s Halaven For Late-Stage Breast Cancer 11/15/2010 SILVER SPRING, Md., Nov. 15, 2010 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. Breast cancer is the second leading […]

Continue Reading

FDA Approval: Ofirmev

November 10, 2010

PRNewswire via COMTEX News Network/ — Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced last week that the U.S. Food and Drug Administration (FDA) has granted marketing approval for OFIRMEV(TM) (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. OFIRMEV is indicated for the management of mild to […]

Continue Reading